Eckert & Ziegler’s GalliaPharm® Generator Powers Groundbreaking Cancer Diagnostic Trial in Japan

Eckert & Ziegler’s GalliaPharm® Generator Powers Groundbreaking Cancer Diagnostic Trial in Japan

(IN BRIEF) Eckert & Ziegler, in collaboration with Novartis Pharma K.K., is expanding Ga-68 labeled diagnostics in Japan through a clinical trial approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Utilizing Eckert & Ziegler’s GalliaPharm® generator, the trial aims to assess the diagnostic efficacy of [68Ga]Ga-DOTA-TATE PET/CT imaging in patients with neuroendocrine neoplasms (NEN), addressing the growing need for advanced cancer diagnostics in Japan.

(PRESS RELEASE) BERLIN, 28-Feb-2024 — /EuropaWire/ — The Eckert & Ziegler Group (ETR: EUZ), one of the world’s largest providers of isotope technology for medical, scientific and industrial use, announces a strategic expansion of its activities in Japan’s diagnostic landscape through a collaborative effort with Novartis Pharma K.K. The joint venture aims to advance Ga-68 labeled diagnostics in Japan, marked by the notification of a clinical trial to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). The trial will exclusively utilize Eckert & Ziegler’s proprietary Ge-68/Ga-68 generator, GalliaPharm®, as the primary source for Ga-68.

The inaugural delivery of GalliaPharm® for the study occurred in January 2024, with subsequent deliveries scheduled until mid-2025. Upon successful market approval, this collaboration is poised to unlock significant sales potential in the Japanese market.

Dr. Harald Hasselmann, CEO of Eckert & Ziegler AG, expressed enthusiasm regarding the partnership’s implications, stating, “We are happy to extend our radioisotope supply business in Japan by contributing our GalliaPharm® to this important clinical research project. But much more importantly, the trial will set the basis for improved access to cancer therapies and diagnostics for Japanese patients.”

The trial, registered under NCT06240741, will focus on assessing the diagnostic efficacy of [68Ga]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging in patients with neuroendocrine neoplasms (NEN). Despite NEN being categorized as rare tumors, their incidence has shown a consistent global rise in recent years.

Eckert & Ziegler and Novartis Pharma K.K.’s collaborative efforts underscore their commitment to advancing medical innovation and addressing the evolving healthcare needs of patients in Japan and beyond.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

Media contact:

Eckert & Ziegler AG
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Karolin Riehle, Investor Relations / Jan Schöpflin, Marketing
karolin.riehle@ezag.de / jan.schoepflin@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

SOURCE: Eckert & Ziegler Strahlen- und Medizintechnik AG